Advances in Pathogenesis and Treatment of Pigmentary Disorders

  • Y. Mishima
Conference paper

Abstract

Since the last Congress, much exciting progress has been made in the study of pigmentary disorders and the underlining process of melanogenesis. Of this progress, I want to concentrate on four areas: mixed eu- and pheomelanogenesis, new regulatory mechanisms of melanogenesis, new depigmenting agents and control of pigment cell neoplasia culminating in a close look at our new, non-surgical melanoma cure using atomic reactor.

Keywords

Carbohydrate Lithium Interferon Myeloma Saponin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mishima Y, Ichihashi M, Mojamdar M (1985) Production, excretion, and regulatory factors of 5-S-Cysteinyldopa genesis in melanoma cells: implications for mixed eu-and pheo-melanogenesis. In: Bagnara J, Klaus SN, Paul E, Schartl M (eds) Proc XIIth Int Pigment Cell Conf, Giessen, FR Germany, Pigment cell. Univ Tokyo Press, Tokyo, pp 709–716.Google Scholar
  2. 2.
    Inazu M, Mishima Y (1987) Pheomelanic congenital macular depigmentation: electron microscopy of hair matrix melanocytes. Presented at the XIVth Annual Meeting on Dermatological Electron Microscopy, Yokohama, April 9.Google Scholar
  3. 3.
    Itoh S, Fujita K (1985) Microanalysis of eumelanin and pheomelanin in hair and melanomas by chemical degradation and liquid chromatography. Anal Biochem 144:527–536.CrossRefGoogle Scholar
  4. 4.
    Mishima Y, Imokawa G (1985) Role of glycosylation in initial melanogenesis post-inhibition dynamics. Pigment Cell 1985. Proc XIIth Intl Pigment Cell Conf, Giessen, FRG, pp 17-30.Google Scholar
  5. 5.
    Mishima Y, Imokawa G (1983) Selective aberration and pigment loss in melanosomes of malignant melanoma cells in vitro by glycosylation inhibitors: premelanosomes as glycoprotein. J Invest Dermatol 81:106–114.PubMedCrossRefGoogle Scholar
  6. 6.
    Ueda M, Mishima Y, Mojamdar M, Ichihashi M, Kita M, Kishida T (1986) Time-dependent suppression of melanoma metastases and natural killer cell activation by interferon. Arch Dermatol Res 278:329–334.PubMedCrossRefGoogle Scholar
  7. 7.
    Irimura T, Gonzales R, Nicolson GL (1981) Effects of tunicamycin on B-6 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties. Cancer Res 41:3411–3418.PubMedGoogle Scholar
  8. 8.
    Hayashibe K, Mishima Y, Ichihashi M, Kawai M (1986) Melanosomal antigenic expression of the cell surface and intracellular subunits within melanogenic compartments of pigment cells: analysis by antimelanosome-associated monoclonal antibody. J Invest Dermatol 87:89–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Mishima Y (1986) Induction of inhibitory controls of melanogenesis. Presented at the Workshop on “Tyrosinase” XIIIth Intl Pigment Cell Conf, Tucson, USA, Oct 5–9.Google Scholar
  10. 10.
    Mishima Y, Shimakage T (1976) Thermal neutron capture treatment of malignant melanoma using 10B-dopa and nB12-chlorpromazine compounds. In: Riley V (ed) Pigment cell 2. Karger, Basel, pp 394–406.Google Scholar
  11. 11.
    Nakanishi T, Ichihashi M, Mishima Y (1980) Thermal neutron capture therapy of malignant melanoma: in vitro radiobiological analysis. Int J Radiat Biol 37(5):573–580.CrossRefGoogle Scholar
  12. 12.
    Mishima Y, Ichihashi M, Nakanishi T, Tsuji M, Ueda M, Nakagawa T, Suzuki T (1984) Cure of malignant melanoma by single thermal neutron capture treatment using melanoma-seeking compounds: 10B/melanogenesis interaction to in vitro/in vivo radiobiological analysis to preclinical studies. In: Fairchild RG, Brownell GL (eds) Proc 1st Int Symp Neutron Capture Therapy, M.I.T., Boston, Oct. 12–14, 1983. BNL (Brookhaven Natl Lab) 51730:355–364.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Y. Mishima
    • 1
  1. 1.Department of DermatologyKobe University School of MedicineKobeJapan

Personalised recommendations